GH Research PLC (GHRS): Price and Financial Metrics
GHRS Price/Volume Stats
| Current price | $8.88 | 52-week high | $14.99 |
| Prev. close | $8.60 | 52-week low | $5.50 |
| Day low | $8.46 | Volume | 61,200 |
| Day high | $9.24 | Avg. volume | 106,973 |
| 50-day MA | $8.48 | Dividend yield | N/A |
| 200-day MA | $10.00 | Market Cap | 462.01M |
GHRS Stock Price Chart Interactive Chart >
GH Research PLC (GHRS) Company Bio
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.
GHRS Price Returns
| 1-mo | 29.64% |
| 3-mo | 18.24% |
| 6-mo | -24.81% |
| 1-year | 46.53% |
| 3-year | -48.34% |
| 5-year | N/A |
| YTD | 26.86% |
| 2024 | 20.69% |
| 2023 | -40.33% |
| 2022 | -58.34% |
| 2021 | N/A |
| 2020 | N/A |
Loading social stream, please wait...